SMMT ivonescimab shows statistically significant OS benefit vs pembrolizumab
SMMT reports ivonescimab monotherapy showed a statistically significant overall survival benefit versus pembrolizumab monotherapy in PD-L1-positive advanced NSCLC in the HARMONi-2 study.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.